The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice
Open accessAbstract
The spike protein (S), a membrane component of severe acute respiratory syndrome coronavirus (SARS-CoV) is anticipated to be an important component of candidate vaccines. We constructed recombinant forms of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S with and without a C-terminal epitope tag called MVA/S-HA and MVA/S, respectively. Cells infected with MVA/Sor MVA/S-HA synthesized a 200-kDa protein, which was recognized by antibody raised against a synthetic peptide of SARS-CoV S or the epitope tag in Western blot analyses. Further studies indicated that S was N - glycosylated and migrated in SDS polyacrylamide gels with an apparent mass of ≈160 kDa after treatment with peptide N-glycosidase F. The acquisition of resistance to endoglycosidase H indicated trafficking of S to the medial Golgi compartment, and confocal microscopy showed that S was transported to the cell surface. Intranasal or intramuscular inoculations of BALB/c mice with MVA/S produced serum antibodies that recognized the SARS S in ELISA and neutralized SARS-CoV in vitro . Moreover, MVA/S administered by either route elicited protective immunity, as shown by reduced titers of SARS-CoV in the upper and lower respiratory tracts of mice after challenge. Passive transfer of serum from mice immunized with MVA/S to naïve mice also reduced the replication of SARS-CoV in the respiratory tract after challenge, demonstrating a role for antibody to S in protection. The attenuated nature of MVA and the ability of MVA/S to induce neutralizing antibody that protects mice support further development of this candidate vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simple method of estimating 50 per cent end points
Muench, H. (1938) · Medical Entomology and Zoology · Cited by 8,376
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Peñaranda, S., Bankamp, B., Maher, K., Chen, M.-H., et al. (2003) · Science · doi:10.1126/science.1085952 · Cited by 2,474
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
The Genome Sequence of the SARS-Associated Coronavirus
Marra, M. A., Jones, S. J. M., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S. N., Khattra, J., Asano, J. K., Barber, S. A., Chan, S. Y., et al. (2003) · Science · doi:10.1126/science.1085953 · Cited by 2,026
The Molecular Biology of Coronaviruses
Lai, M. M. C., & Cavanagh, D. (1997) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60286-9 · Cited by 1,143
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D., Laman, J. D., de Jong, T., van Doornum, G., Lim, W., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,020
Coronavirus Spike Proteins in Viral Entry and Pathogenesis
Gallagher, T. M., & Buchmeier, M. J. (2001) · Virology · doi:10.1006/viro.2000.0757 · Cited by 658
Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter, G., & Moss, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10847 · Cited by 600
Self-citationSui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
Moss, B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11341 · Cited by 515
Self-citationAntoine, G., Scheiflinger, F., Dorner, F., & Falkner, F. G. (1998) · Virology · doi:10.1006/viro.1998.9123 · Cited by 507
Meyer, H., Sutter, G., & Mayr, A. (1991) · Journal of General Virology · doi:10.1099/0022-1317-72-5-1031 · Cited by 474
Subbarao, K., McAuliffe, J., Vogel, L., Fahle, G., Fischer, S., Tatti, K., Packard, M., Shieh, W.-J., Zaki, S., & Murphy, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3572-3577.2004 · Cited by 406
Self-citationThe SARS-CoV S glycoprotein: expression and functional characterization
Xiao, X., Chakraborti, S., Dimitrov, A. S., Gramatikoff, K., & Dimitrov, D. S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.054 · Cited by 370
Blanchard, T. J., Andrea, P., Alcami, A., & Smith, G. L. (1998) · Journal of General Virology · doi:10.1099/0022-1317-79-5-1159 · Cited by 336
Carroll, M. W., & Moss, B. (1997) · Virology · doi:10.1006/viro.1997.8845 · Cited by 331
Self-citationVennema, H., de Groot, R. J., Harbour, D. A., Dalderup, M., Gruffydd-Jones, T., Horzinek, M. C., & Spaan, W. J. (1990) · Journal of Virology · doi:10.1128/jvi.64.3.1407-1409.1990 · Cited by 277
Wyatt, L. S., Earl, P. L., Eller, L. A., & Moss, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401165101 · Cited by 247
Self-citationIs CD46 the cellular receptor for measles virus?
Buckland, R., & Fabian Wild, T. (1997) · Virus Research · doi:10.1016/s0168-1702(96)01421-9 · Cited by 229
SARS coronavirus: a new challenge for prevention and therapy
Holmes, K. V. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18819 · Cited by 223
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
Stittelaar, K. J., Kuiken, T., de Swart, R. L., van Amerongen, G., Vos, H. W., Niesters, H. G. M., van Schalkwijk, P., van der Kwast, T., Wyatt, L. S., Moss, B., et al. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00075-5 · Cited by 188
Self-citationOlsen, C. W., Corapi, W. V., Ngichabe, C. K., Baines, J. D., & Scott, F. W. (1992) · Journal of Virology · doi:10.1128/jvi.66.2.956-965.1992 · Cited by 179
Corapi, W. V., Olsen, C. W., & Scott, F. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6695-6705.1992 · Cited by 142
SARS: Lessons Learned from Other Coronaviruses
Navas, S., & Weiss, S. R. (2003) · Viral Immunology · doi:10.1089/088282403771926292 · Cited by 57
Cited by
COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses
Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.03.005 · Cited by 3,536
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Vincent, M. J., Bergeron, E., Benjannet, S., Erickson, B. R., Rollin, P. E., Ksiazek, T. G., Seidah, N. G., & Nichol, S. T. (2005) · Virology Journal · doi:10.1186/1743-422x-2-69 · Cited by 1,811
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
The Severe Acute Respiratory Syndrome
Peiris, J. S. M., Yuen, K. Y., Osterhaus, A. D. M. E., & Stöhr, K. (2003) · New England Journal of Medicine · doi:10.1056/nejmra032498 · Cited by 1,346
Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus
Weiss, S. R., & Navas-Martin, S. (2005) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.69.4.635-664.2005 · Cited by 1,256
Metadata
- Authors
- Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., Subbarao, K., & Moss, B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2004-04-19
- Volume
- 101
- Issue
- 17
- Pages
- 6641-6646
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2010424791
- Cited by
- 420
- References
- 28
- FWCI
- 32.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.